اخبار و اعلانات

 آمار

تعداد نشریات24
تعداد شماره‌ها881
تعداد مقالات7,867
تعداد مشاهده مقاله14,709,707
تعداد دریافت فایل اصل مقاله12,557,339
Duong, Thu, Araujo Rincon, Mariana, Myneni, Nishanth, Burleson, Marieke. (1402). Genetic alterations in MED12 promote castration-resistant prostate cancer through modulation of GLI3 signaling. , 12(2), 63-70. doi: 10.22099/mbrc.2023.47346.1828
Thu Minh Duong; Mariana Araujo Rincon; Nishanth Myneni; Marieke Burleson. "Genetic alterations in MED12 promote castration-resistant prostate cancer through modulation of GLI3 signaling". , 12, 2, 1402, 63-70. doi: 10.22099/mbrc.2023.47346.1828
Duong, Thu, Araujo Rincon, Mariana, Myneni, Nishanth, Burleson, Marieke. (1402). 'Genetic alterations in MED12 promote castration-resistant prostate cancer through modulation of GLI3 signaling', , 12(2), pp. 63-70. doi: 10.22099/mbrc.2023.47346.1828
Duong, Thu, Araujo Rincon, Mariana, Myneni, Nishanth, Burleson, Marieke. Genetic alterations in MED12 promote castration-resistant prostate cancer through modulation of GLI3 signaling. , 1402; 12(2): 63-70. doi: 10.22099/mbrc.2023.47346.1828

Genetic alterations in MED12 promote castration-resistant prostate cancer through modulation of GLI3 signaling

Molecular Biology Research Communications
دوره 12، شماره 2، 2023، صفحه 63-70    اصل مقاله (404.38 K)
نوع مقاله: Original article
شناسه دیجیتال (DOI): 10.22099/mbrc.2023.47346.1828
نویسندگان
Thu Minh Duong1؛ Mariana Araujo Rincon2؛ Nishanth Myneni2؛ Marieke Burleson* 2
1Department of Molecular Medicine, UT Health San Antonio, San Antonio, TX, USA
2Department of Biology, University of the Incarnate Word, San Antonio, TX, USA
چکیده
Prostate cancer is a disease that depends on androgenic stimulation and is thus commonly treated with androgen deprivation therapy (ADT). ADT is highly successful initially; however, patients inevitably relapse at which point the cancer grows independently of androgens and is termed castration-resistant prostate cancer (CRPC). CRPC develops through various mechanisms, one of these being crosstalk of the androgen receptor (AR) signaling pathway with other signaling pathways. Congruently, prior work has shown that androgen deprivation induces SHH signaling, which subsequently promotes activation of AR-dependent gene expression to promote cell growth. Mechanistically, this crosstalk involves a physical interaction between AR and components of SHH signaling, specifically proteins of the GLI transcription factor family. These findings thus suggest that activation of SHH signaling could promote the recurrence of cell growth in the absence of androgens to ultimately lead to progression towards CRPC. In this study, we have investigated this mechanism in a subset of prostate cancer that harbors genetic alterations within the Mediator subunit 12 (MED12). We found that loss of MED12 promotes the expression of GLI3 target genes which subsequently drives excessive cell growth in the absence of androgens. Thus, we conclude that genetic alterations within MED12 promote CRPC through hyperactivated GLI3 dependent sonic hedgehog signaling.
کلیدواژه‌ها
MED12؛ castration-resistant prostate cancer؛ SHH signaling؛ GLI3؛ tumorigenesis
مراجع
  1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics 2023; CA Cancer Clin 2023;73:17-48.
  2. G. Attard, C. Parker, R.A. Eeles, F. Schröder, S.A. Tomlins, I. Tannock, C.G. Drake, J.S. de Bono. Prostate cancer. Lancet (London, England) 2016; 387:70-82.
  3. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013; 190:429-438.
  4. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: A comprehensive review of available therapies. J Urol 2015;194:1537-1547.
  5. Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol 2013; 138:248-256.
  6. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature reviews. Nat Rev Cancer 2015;15:701-711.
  7. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501-5511.
  8. Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2014;33:2815-2825.
  9. Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science 2004;304:1755-1759.
  10. Peng YC, Joyner AL. Hedgehog signaling in prostate epithelial-mesenchymal growth regulation. Dev Biol 2015;400:94-104.
  11. Shaw A, Bushman W. Hedgehog signaling in the prostate. J Urol 2007;177:832-838.
  12. Dai P, Akimaru H, Tanaka Y, Maekawa T, Nakafuku M, Ishii S. Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. J Biol Chem 1999;274:8143-8152.
  13. Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf AM, Aberger F, Quinn A, Philpott M. GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol 2004;122:1503-1509.
  14. Altaba ARI, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends in Cell Biol 2007;17:438-447.
  15. Sigafoos AN, Paradise BD, Fernandez-Zapico ME. Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease. Cancers (Basel) 2021;13:3410.
  16. Wang W, Shiraishi R, Kawauchi D. Sonic hedgehog signaling in cerebellar development and cancer. Front Cell Dev Biol 2022;10:864035.
  17. Chen M, Carkner R, Buttyan R. The hedgehog/Gli signaling paradigm in prostate cancer. Expert Rev Endocrinol Metab 2011;6:453-467.
  18. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, Buttyan R. Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 2009;8:149-157.
  19. Gowda PS, Deng JD, Mishra S, Bandyopadhyay A, Liang S, Lin S, Mahalingam D, Sun LZ. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression. Mol Cancer Res 2013;11: 1448-1461.
  20. Ibuki N, Ghaffari M, Pandey M, Iu I, Fazli L, Kashiwagi M, Tojo H, Nakanishi O, Gleave ME, Cox ME. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer 2013;133:1955-1966.
  21. Li N, Truong S, Nouri M, Moore J, Al Nakouzi N, Lubik AA, Buttyan R. Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcription-nally active androgen receptor proteins with Gli3. Oncogene 2018;37:2313-2325.
  22. Shaw G, Price AM, Ktori E, Bisson I, Purkis PE, McFaul S, Oliver RT, Prowse DM. Hedgehog signalling in androgen independent prostate cancer. Eur Urol 2008;54:1333-1343.
  23. Chen M, Feuerstein MA, Levina E, Baghel P, Carkner RD, Tanner MJ, Shtutman M, Vacherot F, Terry S, de la Taille A, Buttyan R. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer 2010;9: 89.
  24. Burleson M, Deng JJ, Qin T, Duong TM, Yan Y, Gu X, Das D, Easley A, Liss MA, Yew PR, Bedolla R, Kumar AP, Ming-Huang TH, Zou Y, Chen Y, Chen CL, Huang H, Sun LZ, Boyer TG. GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer. Mol Cancer Res 2022; 20:62-76.
  25. Zhou H, Kim S, Ishii S, Boyer TG. Mediator modulates Gli3-dependent sonic hedgehog signaling. Mol Cell Biol 2006;26:8667-8682.
  26. Zhou H, Spaeth JM, Kim NH, Xu X, Friez MJ, Schwartz CE, Boyer TG. MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling. Proc Natl Acad Sci U S A 2012;109:19763-19768.
  27. Kornberg RD. Mediator and the mechanism of transcriptional activation. Trends Biochem Sci 2005;30:235-239.
  28. Clark AD, Oldenbroek M, Boyer TG. Mediator kinase module and human tumorigenesis. Crit Rev Biochem Mol Biol 2015;50:393-426.
  29. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-689.
  30. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-243.
آمار
تعداد مشاهده مقاله: 923
تعداد دریافت فایل اصل مقاله: 889


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب